Head-to-head evidence
albuterol sulfate (Amphastar) vs fenoterol
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: Beta-2 adrenergic receptor · full Asthma pipeline
albuterol sulfate (Amphastar)
Developed by Amphastar Pharmaceuticals, Inc.
NCT01581177 · Phase 2 · completed
The study randomized 23 participants and used triple blinding with placebo and active albuterol comparators, but its small sample and unreported results limit the strength of the evidence. The primary outcome was change in FEV1 AUC, a physiological surrogate measure, and the registry does not state whether this comparison was successful.
Next expected readout: April 2028 · NCT07426458 (registry estimate)
fenoterol
Developed by Boehringer Ingelheim
NCT02177370 · Phase 3 · terminated
This was a randomized, double-blind, active-controlled crossover study, but it enrolled only 19 participants and one of its two primary measures is a laboratory receptor-density biomarker rather than a direct asthma outcome, and no results have been posted.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: albuterol sulfate (Amphastar)'s landscape · fenoterol's landscape